These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 11827360)

  • 1. Cyclo-oxygenase-1/cyclo-oxygenase-2 non selective non-steroidal anti-inflammatory drugs: epidemiology of gastrointestinal events.
    Lanas A
    Dig Liver Dis; 2001 Dec; 33 Suppl 2():S29-34. PubMed ID: 11827360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective cyclo-oxygenase-2 inhibitors: cardiovascular and gastrointestinal toxicity.
    Wallace JL; Muscará MN
    Dig Liver Dis; 2001 Dec; 33 Suppl 2():S21-8. PubMed ID: 11827359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gastroprotective and ulcer healing effects of nitric oxide-releasing non-steroidal anti-inflammatory drugs.
    Brzozowski T; Konturek PC; Konturek SJ; Sliwowski Z; Drozdowicz D; Kwiecień S; Pajdo R; Ptak A; Pawlik M; Hahn E
    Dig Liver Dis; 2000 Oct; 32(7):583-94. PubMed ID: 11142556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review article: prevention of non-steroidal anti-inflammatory drug gastrointestinal complications--review and recommendations based on risk assessment.
    Chan FK; Graham DY
    Aliment Pharmacol Ther; 2004 May; 19(10):1051-61. PubMed ID: 15142194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.
    Silverstein FE; Faich G; Goldstein JL; Simon LS; Pincus T; Whelton A; Makuch R; Eisen G; Agrawal NM; Stenson WF; Burr AM; Zhao WW; Kent JD; Lefkowith JB; Verburg KM; Geis GS
    JAMA; 2000 Sep; 284(10):1247-55. PubMed ID: 10979111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs.
    Patrono C; Patrignani P; García Rodríguez LA
    J Clin Invest; 2001 Jul; 108(1):7-13. PubMed ID: 11435450
    [No Abstract]   [Full Text] [Related]  

  • 7. Gastro-duodenal protection in an era of cyclo-oxygenase-2-selective nonsteroidal anti-inflammatory drugs.
    Naesdal J; Wilson I
    Eur J Gastroenterol Hepatol; 2001 Dec; 13(12):1401-6. PubMed ID: 11742186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COX-2-selective inhibitors and the risk of upper gastrointestinal bleeding in high-risk patients with previous gastrointestinal diseases: a population-based case-control study.
    Nørgård B; Pedersen L; Johnsen SP; Tarone RE; McLaughlin JK; Friis S; Sørensen HT
    Aliment Pharmacol Ther; 2004 Apr; 19(7):817-25. PubMed ID: 15043523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The gastrointestinal effects of nonselective NSAIDs and COX-2-selective inhibitors.
    Laine L
    Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):25-32. PubMed ID: 12528071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of non-steroidal anti-inflammatory drug-gastropathy.
    Fiorucci S; Antonelli E; Morelli A
    Dig Liver Dis; 2001 Dec; 33 Suppl 2():S35-43. PubMed ID: 11827361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidemiology of NSAID-related gastroduodenal mucosal injury.
    Aalykke C; Lauritsen K
    Best Pract Res Clin Gastroenterol; 2001 Oct; 15(5):705-22. PubMed ID: 11566036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced incidence of upper gastrointestinal ulcer complications with the COX-2 selective inhibitor, valdecoxib.
    Goldstein JL; Eisen GM; Agrawal N; Stenson WF; Kent JD; Verburg KM
    Aliment Pharmacol Ther; 2004 Sep; 20(5):527-38. PubMed ID: 15339324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COX-2 inhibitors vs. NSAIDs in gastrointestinal damage and prevention.
    Ballinger A; Smith G
    Expert Opin Pharmacother; 2001 Jan; 2(1):31-40. PubMed ID: 11336566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events.
    Hunt RH; Harper S; Watson DJ; Yu C; Quan H; Lee M; Evans JK; Oxenius B
    Am J Gastroenterol; 2003 Aug; 98(8):1725-33. PubMed ID: 12907325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A magic bullet for mucosal protection...and aspirin is the trigger!
    Wallace JL; Fiorucci S
    Trends Pharmacol Sci; 2003 Jul; 24(7):323-6. PubMed ID: 12871661
    [No Abstract]   [Full Text] [Related]  

  • 16. NSAIDs, coxibs, CINOD and H2S-releasing NSAIDs: what lies beyond the horizon.
    Fiorucci S; Santucci L; Distrutti E
    Dig Liver Dis; 2007 Dec; 39(12):1043-51. PubMed ID: 17997373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy.
    Wolfe F; Anderson J; Burke TA; Arguelles LM; Pettitt D
    J Rheumatol; 2002 Mar; 29(3):467-73. PubMed ID: 11908558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis.
    Hippisley-Cox J; Coupland C; Logan R
    BMJ; 2005 Dec; 331(7528):1310-6. PubMed ID: 16322018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathogenesis of NSAID-induced gastroduodenal mucosal injury.
    Wallace JL
    Best Pract Res Clin Gastroenterol; 2001 Oct; 15(5):691-703. PubMed ID: 11566035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of non-steroidal anti-inflammatory drug (NSAID) damage in the human gastrointestinal tract.
    James MW; Hawkey CJ
    Br J Clin Pharmacol; 2003 Aug; 56(2):146-55. PubMed ID: 12895187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.